A multicenter, Phase 1b, double-blind, placebo-controlled study to evaluate the safety and tolerability, and the efficacy of si-544 in adults with psoriasis vulgaris or psoriatic arthritis
This study is looking into a new medication called si-544 for adults who have psoriasis or psoriatic arthritis. It's a Phase 1b study, which means it's one of the first times this new medicine is being tested in a small group of people. The main goals are to see if si-544 is safe to use, if people can tolerate it well, and if it shows any signs of helping with the symptoms of these conditions. To make sure results are fair, some participants will receive the actual medicine, while others will get a placebo (a dummy treatment) without knowing which one they are getting. This helps researchers understand the true effects of si-544.
At a glance
What is this study about?
This research study is focused on understanding a new medicine, si-544, and its potential for treating adults living with psoriasis or psoriatic arthritis. Psoriasis is a condition that causes red, scaly patches on the skin, while psoriatic arthritis can cause pain and swelling in the joints, as well as skin changes.
This particular study is called a 'Phase 1b' trial. This means it's an early stage of testing for a new medicine. At this stage, doctors are mainly looking to see if the medicine is safe for people to take, and if they experience any side effects. They also want to get an idea of whether the medicine shows any promise in treating the conditions it's designed for. This is a crucial step before the medicine can be tested in larger groups of people.
The study is designed so that neither the patient nor their doctor will know if they are receiving the experimental medicine (si-544) or a placebo. A placebo looks just like the real medicine but contains no active ingredients. This 'double-blind' approach helps ensure that any changes observed are truly due to the medicine being tested and not influenced by expectations. By carefully gathering information, researchers hope to learn if si-544 could be a helpful new treatment option in the future.
Key takeaways
- This study is testing a new medicine for psoriasis and psoriatic arthritis.
- It's an early-stage study focused on safety and early signs of effectiveness.
- Participants will receive either the new medicine or a dummy treatment.
- It involves regular clinic visits for health checks and monitoring.
- Participation is voluntary, and you can withdraw at any time.
- It's for adults aged 18 or older with these conditions.
Who may be eligible?
To be considered for this study, you must be an adult aged 18 or older. The study is open to both men and women. You would need to have been diagnosed with either psoriasis vulgaris, which is a common type of psoriasis affecting the skin, or psoriatic arthritis, which affects both the skin and the joints.
There might be other specific health requirements or conditions that would mean you can't join the study, even if you have psoriasis or psoriatic arthritis and are over 18. These often relate to your overall health, other medicines you might be taking, or certain medical history. These will be discussed in detail by the study team.
The study team will carefully review your medical history and current health to make sure that taking part is safe for you and that you meet all the necessary criteria. It's important to be open and honest about your health when discussing it with them.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of psoriasis vulgaris?
- Or do you have a diagnosis of psoriatic arthritis?
- Are you willing to attend regular clinic appointments?
- Are you able to follow study instructions carefully?
What does participation involve?
If you decide to take part in this study, you would receive either the new medicine, si-544, or a dummy treatment (placebo). You wouldn't know which one you are getting. You would need to attend several visits to the study clinic over a period of time. During these visits, the study team would:
* Perform physical examinations to check your overall health. * Take blood and urine samples to monitor your body's response and check for safety. * Ask you questions about your symptoms and how you are feeling. * Check for any side effects you might be experiencing.
They may also take measurements related to your psoriasis or psoriatic arthritis to see if the treatment is having any effect. The total length of the study and how many visits are needed will be fully explained to you before you commit to joining.
Potential risks and benefits
Locations (1)
- —UnverifiedGermany
Common questions
What is a 'Phase 1b' study?
It's an early stage of testing a new medicine. The main goals are to see if it's safe and if people can tolerate it well, and to gather very early information on whether it might help treat the condition.
What is a placebo?
A placebo is a 'dummy' treatment that looks exactly like the real medicine but contains no active ingredients. It helps researchers understand the true effects of the study drug.
Who can take part in this study?
Adults aged 18 or over who have either psoriasis vulgaris or psoriatic arthritis may be eligible. Specific health checks will confirm if you can join.
Will I know if I'm getting the real medicine?
No, this is a 'double-blind' study, meaning neither you nor your doctor will know if you're receiving si-544 or the placebo until the study is over.
Can I leave the study if I change my mind?
Yes, you have the right to withdraw from the study at any time, for any reason, without affecting your current or future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.